Outlook Therapeutics
OTLK
56 hedge funds and large institutions have $89.9M invested in Outlook Therapeutics in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 47 closing their positions.
652% more capital invested
Capital invested by funds: $12M → $89.9M (+$78M)
57.47% more ownership
Funds ownership: 0.58% → 58.05% (+57%)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
36% less funds holding
Funds holding: 87 → 56 (-31)
66% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$13.1M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12M |
| 3 |
AC
Armistice Capital
New York
|
+$5.78M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.62M |
| 5 |
CP
Caligan Partners
New York
|
+$4.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$311K |
| 2 |
BlackRock
New York
|
-$116K |
| 3 |
CKAIS
Christensen King & Associates Investment Services
Richland,
Washington
|
-$64.5K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$61.2K |
| 5 |
MCA
MSH Capital Advisors
Scottsdale,
Arizona
|
-$58.5K |
OTLK Hedge Fund Activity: Q1 2024 in Review
56 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2024, worth a combined $89.9M — up 652% from $12M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of OTLK and 16 opened new positions — a net loss of 31 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $13.1M. The largest seller was Morgan Stanley, cutting an estimated $311K.
- 56 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2024, down from 87 in Q4 2023.
- Funds reported $89.9M of Outlook Therapeutics stock for Q1 2024, up 652% quarter-over-quarter.
- 16 funds opened new Outlook Therapeutics positions in Q1 2024 and 47 closed out, a net change of -31 holders.
- The largest Outlook Therapeutics buyer in Q1 2024 was Tang Capital Management, an estimated $13.1M added.
- The largest Outlook Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $311K sold.
Based on aggregated 13F filings for Q1 2024.